Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma

Wong, Grace Lai–Hung; Chan, Henry Lik‐Yuen; Yiu, Karen; Lai, Jennifer Wing-Yan; Chan, Victor J.; Cheung, Ka Shing; Wong, Eleanor; Wong, Vincent Wai‐Sun

doi:10.1111/apt.12207

Cited by 92 publications

(62 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other known HCC risk factors in non-treated patients with HBV infection include older age, male gender, HBeAg status, greater HBV DNA level, and genotype C HBV 5 20 21. Older age and male gender, which are well known risk factors for HCC in non-treated patients,17–19 were independent risk factors for the development of HCC in our NUC CR group (p<0.001).…”

Section: Discussionmentioning

confidence: 67%

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

Cho

Paik

Sohn

et al. 2014

Gut

156

162

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 67%

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

Cho

Paik

Sohn

et al. 2014

Gut

156

162

View full text Add to dashboard Cite

show abstract

“…It is known that HBV genotype C infection, compared to genotype B, is associated with delayed HBeAg seroconversion and disease progression, such as hepatitis, cirrhosis and HCC. 6,10,12,21,30,31 In this study, we have…”

Section: Discussionmentioning

confidence: 99%

Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection

Tseng

Liu

Chen

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Among different genotypes, genotype C is associated with delayed HBeAg seroconversion [33]. Because of longer immune clearance phase and prolonged liver injury, patients with HBV genotype C infection are more likely to develop cirrhosis [34] and have a 2-to 5-fold increase in the risk of HCC [35][36][37][38]. Furthermore, the T1762/A1764 basal core promoter mutant is more common in genotype C [39].…”

Section: Viral Factorsmentioning

confidence: 99%

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Wong

Janssen

2015

Journal of Hepatology

104

111

View full text Add to dashboard Cite

Chronic hepatitis B is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Accurate prediction of HCC risk is important for decisions on antiviral therapy and HCC surveillance. In the last few years, a number of Asian groups have derived and validated several HCC risk scores based on well-known risk factors such as cirrhosis, age, male sex and high viral load. Overall, these scores have high negative predictive values of over 95% in excluding HCC development in 3 to 10 years. The REACH-B score was derived from a community cohort of non-cirrhotic patients and is better applied in the primary care setting. In contrast, the GAG-HCC and CU-HCC scores were derived from hospital cohorts and include cirrhosis as a major integral component. While the latter scores may be more applicable to patients at specialist clinics, the diagnosis of cirrhosis based on routine imaging and clinical parameters can be inaccurate. To this end, recent developments in non-invasive tests of liver fibrosis may further refine the risk prediction. The application of HCC risk scores in patients on antiviral therapy and in other ethnic groups should be evaluated in future studies.

show abstract

Meta‐analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma

Abstract: SUMMARY BackgroundA meta-analysis on the risk of hepatocellular carcinoma (HCC) among hepatitis B virus (HBV) genotypes is warranted as the current data are conflicting.

Cited by 92 publications

References 73 publications

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Contact Info

Product

Resources

About